Evidence map›Paper›PMID 17711996›Full record

Trial reportAmerican journal of physiology. Endocrinology and metabolism2007

Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride.

Ananda Basu, Nisha Charkoudian, William Schrage, Robert A Rizza, Rita Basu, Michael J Joyner

3 registry-linked trialsAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in American journal of physiology. Endocrinology and metabolism, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 101 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 4 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04133922 early_phase1withdrawnstarted 2019, after this paper: background citation

Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes

Ran2019Enrolled0Registered outcomes5Posted comparisons0ConditionsInsulin Sensitivity/Resistance, Type 1 DiabetesArmsDextrose 20 % in Water, GLP-1, Insulin
PMID 27295427PMID 27436611PMID 28479155PMID 15983263PMID 16567818PMID 18612041PMID 1874938PMID 20739685PMID 21610226PMID 2189893PMID 23657563PMID 24658303other papers from this trial
Open the trial in the graph
NCT04575844 phase4recruitingstarted 2020, after this paper: background citation

Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome

Ran2020Enrolled80Registered outcomes6Posted comparisons0ConditionsMetabolic SyndromeArmsExercise Training, liraglutide, Liraglutide + Exercise training
PMID 28237263PMID 27295427PMID 14981009PMID 10600857PMID 10843167PMID 11078458PMID 11916935PMID 12107720PMID 12791603PMID 14966043PMID 15084712PMID 15161743other papers from this trial
Open the trial in the graph
NCT05478707 phase2recruitingstarted 2023, after this paper: background citation

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

Ran2023Enrolled47Registered outcomes5Posted comparisons0ConditionsDiabetes Mellitus, Type 1, Endothelial DysfunctionArmsDulaglutide, Placebo
PMID 29310645PMID 24742660PMID 22732108PMID 27295427PMID 27436611PMID 27633186PMID 26082639PMID 11842075PMID 1348845PMID 15161743PMID 16109070PMID 16644702other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 4 syntheses or guidelines pooled it, 221 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans.American journal of physiology. Regulatory, integrative and comparative physiology · 2008
    Trial
  20. Review

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ananda BasuDivision of Endocrinology & Metabolism, 5-193 Joseph, Saint Mary's Hospital, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. basu.ananda@mayo.edu
Nisha Charkoudian
William Schrage
Robert A Rizza
Rita Basu
Michael J Joyner
Mayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sulfonylureas (SU) with glucagon-like peptide-1 (GLP-1)-based therapy are an emerging therapeutic combination for type 2 diabetes. Prior human studies have hinted at endothelial effects of GLP-1 and SU. To study the endothelial effects of GLP-1 per se and to evaluate the modulatory effects, if any, of SU agents on GLP-1-induced changes in endothelial function, healthy, nondiabetic, normotensive, nonsmokers, age 18-50 yr with no family history of diabetes, were studied. Subjects were randomized to either placebo (n = 10), 10 mg of glyburide (n = 11), or 4 mg of glimepiride (n = 8) orally. Euglycemic somatostatin pancreatic clamp with replacement basal insulin, glucagon, and growth hormone was performed for 240 min. Forearm blood flow (FBF) was measured by venous occlusion plethysmography with graded brachial artery infusions of acetylcholine (Ach) and nitroprusside (NTP) before and after intravenous infusion of GLP-1. GLP-1 (preinfusion 3.4 +/- 0.2, postinfusion 25.5 +/- 2.8 pM) enhanced (P < 0.03) Ach-mediated vasodilatation (Delta+6.5 +/- 1.1 vs. Delta+9.1 +/- 1.2 ml.100 ml(-1).min(-1), change from baseline FBF) in those on placebo. However, in contrast, glyburide abolished GLP-1-induced Ach-mediated vasodilatation (Delta+11.7 +/- 2.0 vs. Delta+11.7 +/- 2.5 ml.100 ml(-1).min(-1)). On the other hand, glimepiride did not alter the ability of GLP-1 to enhance Ach-mediated vasodilatation (Delta+7.9 +/- 0.5 vs. Delta+10.2 +/- 1.3 ml.100 ml(-1).min(-1), P < 0.04). Neither GLP-1 nor SU altered NTP-induced vasodilatation. These data demonstrate that GLP-1 per se has direct beneficial effects on endothelium-dependent vasodilatation in humans that are differentially modulated by SU.

Indexed as

AcetylcholineAdultBlood GlucoseC-Reactive ProteinDrug InteractionsEndothelium, VascularFemaleForearmGlucagon-Like Peptide 1GlyburideHumansHypoglycemic AgentsIncretinsInsulinMaleNitroprussideAcetylcholineBlood GlucoseC-Reactive ProteinglimepirideGlucagon-Like Peptide 1GlyburideHypoglycemic AgentsIncretinsInsulinNitroprussideSulfonylurea CompoundsVasodilator Agents

Identifiers

PMID17711996
OpenAlexW2169562373

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.